Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient

Size: px
Start display at page:

Download "Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient"

Transcription

1 Pharmacokinetics and Pharmacodynamics of Antimicrobials in the Critically Ill Patient Rania El-Lababidi, Pharm.D., BCPS (AQ-ID), AAHIVP Manager, Pharmacy Education and Training Cleveland Clinic Abu Dhabi

2 Objectives Basic Pharmacokinetics and Pharmacodynamics (PK/PD) principles of antimicrobials Importance of PK/PD of antimicrobials in critically ill patients PK/PD parameters of common antimicrobials Recent literature and clinical applications of PK/PD of antimicrobials i in the critically ill

3 Drusano s Patient A patient was admitted to the intensive care unit with Klebsiella pneumoniae pneumonia. As with any great case, I and the other residents would seek the wise counsel of Dr. Woodward. I ran up to him in the hallway, presented the case quickly, and said Dr. Woodward, we re treating the patient with cefazolin plus gentamicin. How much should we give him and for how long? After about 5 seconds of consideration, Dr. Woodward said George, you treat him with enough and you treat him for long enough! Dr. G. L. Drusano

4 Antimicrobial Therapy in the ICU Initial inappropriate antimicrobial therapy associated with increased mortality Surviving Sepsis Guidelines Administer antibiotics within an hour Broad-spectrum antibiotics with good tissue penetration Reassess antimicrobials daily What about appropriate initial dosing of antimicrobials? Suboptimal outcomes even if initial antimicrobial choice is appropriate Dellinger RP. CCM 2013; 41: Zilberberg MD et al.chest 2008;134: Pea F, Viale P. CID 2006; 42:

5 Antimicrobial Therapy Puzzle Source: Adapted from Pea et al. CID 2006;42:

6 Basic Principles MIC Minimum m concentration of antibiotic necessary to inhibit growth of bacteria MBC Minimum concentration necessary to kill bacteria

7 Basic Principles Bacteriostatic agents Agents that inhibit antimicrobial growth: e.g. clindamycin, cin azithromycin, tetracyclines, linezolid, chloramphenicol MIC < MBC Bactericidal agents Agents that rapidly kill bacteria e.g. beta-lactams, daptomycin, vancomycin, metronidazole, FQs MIC = MBC

8 From Bedside to Bench Pharmacokinetics The interrelationship between een drug dose and variations in concentrations in plasma and tissue over time Cmax: Peak concentration after a single dose Vd: Volume of distribution of drug administered Clearance (CL): loss of drug through metabolism or excretion e Elimination half-life (t ½ ): time required for the drug plasma concentration to fall by one-half AUC 24 : total area under the concentration curve over 0 to 24 h

9 Pharmacokinetics of Antimicrobials Oral administration Drug s bioavailability ailabilit e.g. FQs vs macrolides Esterified cephalosporins e.g. cefuroxime axetil Disease states that lower bioavailability e.g. sepsis IV Administration Bolus administration Extended infusion Continuous infusion

10 Pharmacokinetics of Antimicrobials Distribution Process by which drug diffuses from the intravascular asc fluid space to extravascular fluid spaces Plasma protein binding, disease states, lipid solubility, molecular size, tissue perfusion, diffusion (prostate, eye, brain) Issues that influence Vd in the critically ill patients Large volume and blood product infusions Positive pressure ventilation Capillary leak and reduction in albumin serum concentrations

11 Pharmacokinetics of Antimicrobials Activity of antimicrobials is influenced by: Protein binding ph of surrounding tissue e.g. aminoglycosides and abscess Slow growing bacteria Presence of a biofilm I t ll l th Chl di Li t i Intracellular pathogens e.g. Chlamydia spp., Listeria spp., Salmonella

12 Solubility Profiles of Antimicrobials β-lactam Penicillins Cephalosporins Carbapenems Glycopeptides Aminoglycosides Macrolides Fluoroquinolones Tetracycline Rifampin Linezolid Limited Vd Renally as unchanged drug Limited diffusion ability Large Vd Intracellular pathogens activity Hepatic metabolism Diffuses freely to plasma membrane Source: Pea et al. CID 2006;42:

13 Question 1 Which of the following antimicrobials would be most effective against Rickettsia spp? a. Penicillin b. Vancomycin c. Doxycycline d. Gentamicin 13

14 Pharmacokinetics of Antimicrobials Elimination Liver: erythromycin, azithromycin, nafcillin, rifampin Renal: β-lactam antibiotics Bile: ceftriaxone Gut: doxycycline

15 Impact of MODS on Antibiotic PK Implication of MODS on Antibiotic Pharmacokinetics GI Dysfunction Tissue Hypoperfusion Hepatic Dysfunction Renal Dysfunction Decreased Decreased Decreased Decreased Decreased absorption of antibiotic tissue protein elimination elimination of enterally concentration binding of of lipophilic hydrophilic administered antibiotics highly bound antibiotics antibiotics antibiotics UNDERDOSING OVERDOSING Source: Ulldemolins M. Chest 2011;139: PK: Pharmacokinetics; MODS: Multiple Organ Dysfunction Syndrome

16 Pharmacokinetic Changes in Critically Ill Patients Healthy Patient Septic Patient Renal Dysfunction Source: Gonçalves-Pereira, Póvoa. Critical Care 2011;15:R206.

17 Optimizing Dosing in Critically Ill Patients Increased Vd and increased clearance of antimicrobials Literature demonstrates suboptimal initial antimicrobial levels Roberts et al., 70% of patients did NOT achieve adequate β-lactam levels Taccone et al., less than 50% of patients achieved adequate PK/PD targets for β-lactam administered Loading Dose Vd x Cp Dose Roberts JA et al. Int J Antimicrob Agents ;36 : Taccone et al. Crit Care ;14: R126.

18 Guidelines for Optimizing Dosing in the Critically Ill Antibiotic Solubility Organ System LD in Patients with increased Vd MD in Kidney Failure MD in Hepatic Failure β-lactam Hydrophilic Renal Administer a high LD initially Decrease dose Normal Dosing Aminoglycosides Hydrophilic Renal Administer a high LD initially Decrease dose; Dose titrated based on levels Normal Dosing Vancomycin Hydrophilic Renal Administer a high LD initially Decrease dose; Dose titrated based on levels Normal Dosing Fluoroquinolones Lipophilic Renal and hepatic Administer normal dose initially Decrease dose based on principal organ responsible for clearance Decrease dose based on principal organ responsible for clearance Glycylcyclines Lipophilic Hepatic Administer a high LD initially Normal dosing Decrease dosing LD: loading dose; MD: Maintenance dose Ulldemolins M et al. Chest 2011;139;

19 Pharmacodynamics of Antimicrobials Antimicrobial pharmacodynamics Links measures of drug exposure to microbiological or clinical effects Affected by: Biochemical and physiological effects of the drug

20 Pharmacodynamic Parameters Time-dependent PK/PD index: ƒt > MIC Cell-wall active agents: Beta-lactams Decrease the interval for re-dosing Concentration-dependent PK/PD index: Cmax/MIC or ƒauc 0-24 /MIC Fluoroquinolones, tetracycline, metronidazole, clindamycin, glycyclines Increase the dose

21 Common Pharmacodynamic Principles Source: Craig WA. CID 1998;26:1-10.

22 Pharmacodynamic (PD) parameters correlating with efficacy Antibacterial Class Optimal PK/PD PK/PD magnitude Parameter required for efficacy Aminoglycosides C max /MIC Fluoroquinolones AUC/MIC > 25, >100 Beta-lactams T>MIC 50%; 70% Linezolid AUC/MIC >80 Daptomycin AUC/MIC 189 Tigecycline AUC/MIC Scaglione F et al. AAC 2008; 32; 4: Rubino CM et al. AAC 2012; 56:

23 Pharmacokinetics Meets Pharmacodynamics Elimination Drug Administration Plasma Concentration Target Site Concentration Pharmacological Effect Pharmacokinetics Pharmacokinetics Pharmacodynamics Pharmacokinetics/Pharmacodynamics Source: Ulldemolins M. Chest 2011;139:

24 Penicillins and Cephalosporins Time-dependent Dosage strategies to maintain T> MIC 60-70% of the time Strategies: extended infusion, continuous infusion

25 Carbapenems Time-dependent T > MIC % of the time Prolonged or extended infusion

26 Quinolones Concentration-dependent AUC/MIC and C max /MIC Gram-negative bacteria: AUC/MIC > 125 Gram-positive bacteria AUC/MIC >

27 Quinolone Pharmacodynamics Lomefloxacin 40 mg/kg q12h Lomefloxacin 80 mg/kg q24h 40% survival 75% survival Adapted from Drusano GL et al. AAC 1993; 37:

28 Quinolones Pharmacokinetic study in patients with nosocomial pneumonia Levofloxacin 750 mg IV q24h AUC/MIC cut-off of 87 Failure to attain this AUC/MIC ratio resulted in failure to eradicate pathogens Drusano GL et al. J Infect Dis 2004;189;

29 Aminoglycosides Concentration-dependent C max /MIC: 8 12 Clinical outcomes well correlated with AUC/MIC Kashuba AD. AAC 1999; 43:

30 Once Daily Dosing of Aminoglycosides Once daily dosing and probability of nephrotoxicity Twice Daily Dosing Once Daily Dosing Source: Rybak MJ et al. AAC 1999;43:

31 Question 2 What percentage of time above the MIC is most ideal for meropenem? A. 80% B. 60% C. 40% D. 20% 31

32 Vancomycin Time dependent AUC/MIC 400 Loading dose mg/kg/dose Nephrotoxicity 5-43% in literature Higher in critically ill patients Trough levels > 20 mg/l Patel N et al. Clin Infect Dis. 2011;52: Van Hal SJ. Antimicrob. Agents Chemother 2013;57:

33 Tigecycline Glycylcycline antibiotic FDA approved for cssti, CAP, ciai Did not meet primary endpoints for HAP or diabetic foot infections Time dependent AUC/MIC Increase in all-cause mortality in tigecycline-treated treated patients in clinical trials Overall mortality rate was higher, compared with comparator antibiotics (RD, 0.7%; 95% [CI],.1 1.2; P =.01) Prasad P. Clin Infect Dis 2012; 54:

34 Tigecycline and Increased Mortality Inadequate antimicrobial activity Tigecyclinecline is a static antimicrobial Non-linear high protein binding Very large Vd (5-10 L/kg) Standard dosing of 100 mg IV, 50 mg q12h Css= 0.6 mcg/ml too low compared to breakpoints Severe infections with bacteremia compound inadequate microbiological response US FDA issued Boxed Warning Prasad P. Clin Infect Dis 2012; 54:

35 Monte-Carlo Simulations Mathematical modeling used to design antimicrobial dosing regimens with optimal PD profiles Integrates t PK/PD profiles and MIC data simulates the dispersion of concentration-time profiles seen in a large population Calculates the probability of target attainment (PTA) at p y g ( ) each MIC value

36 Monte-Carlo Simulations Source: De Ryke A et al. Diag Mic Inf Dis 2007;58:

37 Extended Infusion β-lactams Extending the infusion Sustained concentrations above the MIC for longer periods Achieve more favorable PK/PD profile even against organisms with higher MICs Prolonged (3 or 4 hours) vs. continuous infusion yield similar PK/PD profiles Source: Kim A. Pharmacotherapy 2007;27:

38 Extended Infusion β-lactams Where is the Evidence? Retrospective, comparative study Two dosing regimens compared in critcially ill patients Piperacillin-tazobactam gm IV q6 4h over 30 min vs Piperacillin-tazobactam gm IV q8h over 4 hours Outcomes of patients with P. aeruginosa retrospectively evaluated ed Lodise TP. Clin Infect Dis 2007;44:

39 Extended Infusion β-lactams Where is the Evidence? Lodise TP. Clin Infect Dis 2007;44:

40 Question 3 A 60 yo male is admitted with MDR P. aeruginosa bacteremia. The MIC to piperacillin-tazobactam is 16 mcg/ml. Which of the regimens would you use in this patient? A. 30 min infusion of piperacillin-tazobactam gm IV q6hr B. 4 hour infusion of piperacillin-tazobactam gm IV q8hr C. Continuous infusion of 18 gm of piperacillintazobactam D. A much stronger antibiotic than piperacillin- tazobactam 40

41 What about prospective data? Dulhunty et al recently conducted a prospective, randomized, double-blind, controlled trial Compared continuous infusion to bolus administration of β-lactams in septic patients 60 patients enrolled into study Study endpoints Primary endpoint: plasma concentrations above the MIC Secondary endpoint: clinical cure Dulhunty et al. Clinical Infectious Diseases 2013;56:

42 Continuous vs. Bolus Administration of β-lactams Percentage of plasma concentration above the MIC Meropenem: 100% in the intervention ention vs 22% inthe control group Piperacillin-tazobactam: 75% in the intervention vs. 36% in the control group Ticarcillin-clavulanate: 50% in the intervention vs. 0% in the control group Dulhunty et al. Clinical Infectious Diseases 2013;56:

43 Continuous vs. Bolus Administration of β-lactams Dulhunty et al. Clinical Infectious Diseases 2013;56:

44 Findings from a Meta-analysis Falagas et al. conducted a meta-analysis of non- randomized studies Compared clinical outcomes of extended or continuous infusion of β-lactams to short infusion Included 14 studies in the meta-analysis Outcomes: Primary outcomes: All-cause mortality and clinical cure Secondary outcomes: emergence of resistance and adverse events Falagas ME. CID 2013;56:

45 Meta-analysis Results Mortality was lower among patients who received extended or continuous infusions β-lactams compared to short infusion RR = 0.59 (95% CI, 0.41, 0.83) Falagas ME. CID 2013;56:

46 Conclusion and Future Directions Careful consideration of antimicrobial dosing in critically ill patients based on PK/PD parameters Extended or continuous infusion β-lactams optimizes outcomes in critically ill patients Additional multicenter trials with sufficient power to delineate differences in outcomes With new antimicrobials developed, pre-clinical PK/PD data is necessary to identify optimal dosing regimens

47 QUESTIONS?

Antimicrobial Pharmacodynamics

Antimicrobial Pharmacodynamics Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they

More information

Introduction to Pharmacokinetics and Pharmacodynamics

Introduction to Pharmacokinetics and Pharmacodynamics Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:

More information

DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams

DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams Jan J. De Waele MD PhD Surgical ICU Ghent University Hospital Ghent, Belgium Disclosures Financial: consultancy for

More information

Antimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill

Antimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill Antimicrobial Pharmacokinetics/dynamics Bedside Applications in the Critically Ill Arthur RH van Zanten, MD PhD Internist-intensivist Department of Intensive care Gelderse Vallei Hospital, Ede The Netherlands

More information

CHSPSC, LLC Antimicrobial Stewardship Education Series

CHSPSC, LLC Antimicrobial Stewardship Education Series CHSPSC, LLC Antimicrobial Stewardship Education Series March 8, 2017 Pharmacokinetics/Pharmacodynamics of Antibiotics: Refresher Part 1 Featured Speaker: Larry Danziger, Pharm.D. Professor of Pharmacy

More information

Antibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals

Antibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals Antibiotic Pharmacokinetics and Pharmacodynamics for Laboratory Professionals Tom Dilworth, PharmD Aurora Health Care thomas.dilworth@aurora.org Objectives Describe the pharmacokinetics and pharmacodynamics

More information

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,

More information

DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*

DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* 44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine

More information

Antimicrobial therapy in critical care

Antimicrobial therapy in critical care Antimicrobial therapy in critical care KARLEE JOHNSTON LEAD PHARMACIST DIVISION OF CRITICAL CARE CANBERRA HOSPITAL AND HEALTH SERVICE Outline 1. Let s talk about sepsis 2. PK/PD considerations 3. Selecting

More information

Jerome J Schentag, Pharm D

Jerome J Schentag, Pharm D Clinical Pharmacy and Optimization of Antibiotic Usage: How to Use what you have Learned in Pharmacokinetics and Pharmacodynamics of Antibiotics Jerome J Schentag, Pharm D Presented at UCL on Thursday

More information

CF WELL Pharmacology: Microbiology & Antibiotics

CF WELL Pharmacology: Microbiology & Antibiotics CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy

Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Building a Better Mousetrap for Nosocomial Drug-resistant Bacteria: use of available resources to optimize the antimicrobial strategy Leonardo Pagani MD Director Unit for Hospital Antimicrobial Chemotherapy

More information

Effective 9/25/2018. Contact for previous versions.

Effective 9/25/2018. Contact for previous versions. Pharmacokinetic and Pharmacodynamic Dose Optimization of Antibiotics (β-lactams, aminoglycosides, and ciprofloxacin) for the Treatment of Gram-Negative Infections Adult Inpatient/Emergency Department Clinical

More information

ICU Volume 14 - Issue 4 - Winter 2014/ Matrix

ICU Volume 14 - Issue 4 - Winter 2014/ Matrix ICU Volume 14 - Issue 4 - Winter 2014/2015 - Matrix Antibiotic Management in the ICU Eleni Patrozou ******@***gmail.com Intensivist - Hygeia Hospital, Athens, Greece Infectious Diseases Division - Alpert

More information

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1 Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Appropriate Antimicrobial Therapy for Treatment of

Appropriate Antimicrobial Therapy for Treatment of Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul

More information

Introduction to Antimicrobial Therapy

Introduction to Antimicrobial Therapy Introduction to Antimicrobial Therapy Christine Kubin, Pharm.D., BCPS Clinical Pharmacist, Infectious Diseases Case #2 68 y.o. female with HTN, anxiety with chest pain symptoms 7/27/05: Cath - 3 vessel

More information

Combating Antimicrobial Resistance with Extended Infusion Beta-lactams. Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident

Combating Antimicrobial Resistance with Extended Infusion Beta-lactams. Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident Combating Antimicrobial Resistance with Extended Infusion Beta-lactams Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident Disclosure The presenter has no conflicts of interest to disclose with material

More information

Disclosure. Objectives. Combating Antimicrobial Resistance with Extended Infusion Beta-lactams

Disclosure. Objectives. Combating Antimicrobial Resistance with Extended Infusion Beta-lactams Combating Antimicrobial Resistance with Extended Infusion Beta-lactams Stephen Andrews, PharmD PGY-1 Pharmacy Practice Resident Disclosure The presenter has no conflicts of interest to disclose with material

More information

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA

More information

Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections

Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg

More information

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA www.ivis.org Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA October 3-5, 2013 Budapest, Hungary Reprinted in IVIS with the Permission of the WEVA Organizers

More information

ANTIMICROBIAL PRESCRIBING Optimization through Drug Dosing and MIC

ANTIMICROBIAL PRESCRIBING Optimization through Drug Dosing and MIC ANTIMICROBIAL PRESCRIBING Optimization through Drug Dosing and MIC PREFACE INTRODUCTION The wide use and frequent misuse of antimicrobials in all countries has resulted in the emergence of drug resistance,

More information

Why we perform susceptibility testing

Why we perform susceptibility testing 22 nd June 2015 Why we perform susceptibility testing Robin A Howe Antimicrobial use in Primary Care Why do we perform AST? Clinical Clinical Prediction Prediction of of Efficacy Efficacy Why do we perform

More information

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010 Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter

More information

Fighting MDR Pathogens in the ICU

Fighting MDR Pathogens in the ICU Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial

More information

Systemic Antimicrobial Prophylaxis Issues

Systemic Antimicrobial Prophylaxis Issues Systemic Antimicrobial Prophylaxis Issues Pierre Moine Department of Anesthesiology University of Colorado Denver 3 rd International Conference on Surgery and Anesthesia OMICs Group Conference The Surgical

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases

More information

Antimicrobial stewardship in managing septic patients

Antimicrobial stewardship in managing septic patients Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest

More information

Introduction to Antimicrobial Therapy

Introduction to Antimicrobial Therapy Case #1 Introduction to Antimicrobial Therapy Christine Kubin, Pharm.D., BCPS Clinical Pharmacist, Infectious Diseases L.G. is a 78 yo woman admitted for cardiac cath. 3-vessel disease was identified and

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

General Infectious Disease Concepts/Resources

General Infectious Disease Concepts/Resources General Infectious Disease Concepts/Resources Learning Objectives: 1. Distinguish between foundational infectious disease concepts including gram positive and negative bacteria, bacteriostatic and bactericidal

More information

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008 Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring Janis Chan Pharmacist, UCH 25-4-2008 2008 Aminoglycosides (AG) 1. Gentamicin 2. Amikacin 3. Streptomycin 4. Neomycin

More information

Animal models and PK/PD. Examples with selected antibiotics

Animal models and PK/PD. Examples with selected antibiotics Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh

More information

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.

More information

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site

More information

Principles of Antimicrobial therapy

Principles of Antimicrobial therapy Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or

More information

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:

More information

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital

More information

Mono- versus Bitherapy for Management of HAP/VAP in the ICU

Mono- versus Bitherapy for Management of HAP/VAP in the ICU Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,

More information

Maximizing the efficacy of antibiotic therapy

Maximizing the efficacy of antibiotic therapy Community Acquired Pneumonia Maximizing the efficacy of antibiotic therapy João Gonçalves Pereira, MD, PhD ICU Director Hospital Vila Franca Xira Antibiotics and Pneumonia Survival in Bacteremic Pneumococcal

More information

Choosing an Antibiotic

Choosing an Antibiotic Principles of Antibiotic Use - The 6 Step Plan Robin J Green MBBCh, DCH, FC Paed, DTM&H, MMed, FCCP, PhD, Dip Allergy, FAAAAI Department of Paediatrics and Child Health 1 Choosing an Antibiotic Disease/Site

More information

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California

More information

Sustaining an Antimicrobial Stewardship

Sustaining an Antimicrobial Stewardship Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial

More information

Other Beta - lactam Antibiotics

Other Beta - lactam Antibiotics Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics

More information

Disclosure. Objectives. Transitions in Care: Inpatient to Outpatient Parenteral Antibiotic Therapy 2/16/2017

Disclosure. Objectives. Transitions in Care: Inpatient to Outpatient Parenteral Antibiotic Therapy 2/16/2017 Transitions in Care: Inpatient to Outpatient Parenteral Antibiotic Therapy Juan E. Villanueva, PharmD, BCPS PGY2 Infectious Diseases University of Arizona Banner University Medical Center Tucson Disclosure

More information

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014

More information

Maximizing the efficacy of antibiotic therapy

Maximizing the efficacy of antibiotic therapy Community Acquired Pneumonia Maximizing the efficacy of antibiotic therapy João Gonçalves Pereira, MD, PhD ICU Director Hospital Vila Franca Xira Antibiotics and Pneumonia Survival in Bacteremic Pneumococcal

More information

Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital

Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a

More information

Objectives. Introduction to Antimicrobial Therapy. What are Antimicrobials??? Classification of Antimicrobials. Case Presentation #1

Objectives. Introduction to Antimicrobial Therapy. What are Antimicrobials??? Classification of Antimicrobials. Case Presentation #1 Introduction to Antimicrobial Therapy Objectives Review the classification of antimicrobials Define pharmacokinetic and pharmacodynamic principles and their relationship to effective antimicrobial therapy

More information

Curricular Components for Infectious Diseases EPA

Curricular Components for Infectious Diseases EPA Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize

More information

Stanford Hospital and Clinics Last Review: 02/2016 Pharmacy Department Policies and Procedures

Stanford Hospital and Clinics Last Review: 02/2016 Pharmacy Department Policies and Procedures Medication Administration: Extended-Infusion Meropenem (Merrem ) Protocol Related Documents: Patient Care Manual Guide: Medication Administration IV Infusion Guidelines I. PURPOSE Meropenem belongs to

More information

Antimicrobial Therapy

Antimicrobial Therapy Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the

More information

Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens

Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens Jared L. Crandon, Pharm.D., BCPS Associate Director, Clinical and Experimental Pharmacology Center for Anti-Infective Research

More information

UPDATES ON ANTIBIOTIC THERAPY. Jennifer L. Davis, DVM, PhD, DACVIM (LA), DACVCP VA-MD College of Veterinary Medicine VA Tech, Blacksburg, VA

UPDATES ON ANTIBIOTIC THERAPY. Jennifer L. Davis, DVM, PhD, DACVIM (LA), DACVCP VA-MD College of Veterinary Medicine VA Tech, Blacksburg, VA UPDATES ON ANTIBIOTIC THERAPY Jennifer L. Davis, DVM, PhD, DACVIM (LA), DACVCP VA-MD College of Veterinary Medicine VA Tech, Blacksburg, VA ANTIBIOTICS Fluoroquinolones The fluoroquinolone class of antibiotics

More information

Should we test Clostridium difficile for antimicrobial resistance? by author

Should we test Clostridium difficile for antimicrobial resistance? by author Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first

More information

Antimicrobial Susceptibility Testing: The Basics

Antimicrobial Susceptibility Testing: The Basics Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories

More information

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis

More information

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse

More information

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY

More information

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه

More information

Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate

Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons

More information

Antibiotics 201: Gramnegatives

Antibiotics 201: Gramnegatives Antibiotics 201: Gramnegatives B. Joseph Guglielmo, Pharm.D. Professor and Dean School of Pharmacy University of California San Francisco Disclosures No potential conflicts of interest. 1 A 77 year old

More information

Percent Time Above MIC ( T MIC)

Percent Time Above MIC ( T MIC) 8 2007 Percent Time Above MIC ( T MIC) 18 8 25 18 12 18 MIC 1 1 T MIC 1 500 mg, 1 2 (500 mg 2) T MIC: 30 (TA30 ) 71.9 59.3 T MIC: 50 (TA50 ) 21.5, 0.1 1,000 mg 2 TA30 80.5, 68.7 TA50 53.2, 2.7 500 mg 3

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

Staph Cases. Case #1

Staph Cases. Case #1 Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling

More information

OPTIMIZING ANTIMICROBIAL PHARMACODYNAMICS: A GUIDE FOR YOUR STEWARDSHIP PROGRAM

OPTIMIZING ANTIMICROBIAL PHARMACODYNAMICS: A GUIDE FOR YOUR STEWARDSHIP PROGRAM Document downloaded from http://www.elsevier.es, day 06/04/2018. This copy is for personal use. Any transmission of this document by any media [REV. or MED. format is CLIN. strictly CONDES prohibited.

More information

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis

More information

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections

ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.

More information

Pierre-Louis Toutain, Ecole Nationale Vétérinaire National veterinary School of Toulouse, France Wuhan 12/10/2015

Pierre-Louis Toutain, Ecole Nationale Vétérinaire National veterinary School of Toulouse, France Wuhan 12/10/2015 Antimicrobial susceptibility testing for amoxicillin in pigs: the setting of the PK/PD cutoff value using population kinetic and Monte Carlo Simulation Pierre-Louis Toutain, Ecole Nationale Vétérinaire

More information

Best Antimicrobials for Staphylococcus aureus Bacteremia

Best Antimicrobials for Staphylococcus aureus Bacteremia Best Antimicrobials for Staphylococcus aureus Bacteremia I. Methicillin Susceptible Staph aureus (MSSA) A. In vitro - Anti-Staphylococcal β-lactams (Oxacillin, Nafcillin, Cefazolin) are more active B.

More information

Antimicrobial Stewardship 101

Antimicrobial Stewardship 101 Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential

More information

Principles of Antimicrobial Therapy

Principles of Antimicrobial Therapy Principles of Antimicrobial Therapy Key Points Early and rapid diagnosis of infection and prompt initiation of appropriate antimicrobial therapy, if warranted, are fundamental to reducing the mortality

More information

Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections

Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections ...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS European Medicines Agency Veterinary Medicines and Inspections London, 12 November 2007 EMEA/CVMP/SAGAM/383441/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC

More information

Optimising treatment based on PK/PD principles

Optimising treatment based on PK/PD principles Optimising treatment based on PK/PD principles Paul M. Tulkens Cellular and Molecular Pharmacology & Center for Clinical Pharmacy Louvain Drug Research Institute Catholic University of Louvain Brussels,

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:

More information

* gender factor (male=1, female=0.85)

* gender factor (male=1, female=0.85) Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12

More information

Clinical Practice Standard

Clinical Practice Standard Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:

More information

SESSION XVI NEW ANTIBIOTICS

SESSION XVI NEW ANTIBIOTICS SESSION XVI NEW ANTIBIOTICS New Antibiotics to Treat Anaerobic Infections 2 Goldstein, E.J.C.;* Citron, D.M. Antibiotic Pharmacodynamics 3 Stein, G.E.* Targeting Selenium Metabolism in Stickland Fermentors:

More information

Introduction to Antimicrobial Therapy

Introduction to Antimicrobial Therapy Introduction to Antimicrobial Therapy Christine Kubin Classification of Antimicrobials Antimicrobials are drugs that destroy microbes, prevent their multiplication or growth, or prevent their pathogenic

More information

Combination vs Monotherapy for Gram Negative Septic Shock

Combination vs Monotherapy for Gram Negative Septic Shock Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham

More information

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES

CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug

More information

LUNCH AND LEARN. January 13, CE Activity Information & Accreditation

LUNCH AND LEARN. January 13, CE Activity Information & Accreditation LUNCH AND LEARN Overview of Antimicrobial Stewardship January 13, 2017 Featured Speaker: Jamie Kisgen, PharmD, BCPS (AQ ID) Pharmacotherapy Specialist Infectious Diseases Antimicrobial Stewardship Program

More information

What do we know on PK/PD of β-lactams

What do we know on PK/PD of β-lactams What do we know on PK/PD of β-lactams Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute Université catholique de Louvain, Brussels, Belgium

More information

Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections

Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections SUPPLEMENT ARTICLE Use of Pharmacokinetics and Pharmacodynamics to Optimize Antimicrobial Treatment of Pseudomonas aeruginosa Infections David S. Burgess College of Pharmacy, University of Texas at Austin,

More information

Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections

Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections ...PRESENTATIONS... Antibiotic Kinetic and Dynamic Attributes for Community-Acquired Respiratory Tract Infections David P. Nicolau, PharmD Presentation Summary Factors, including the age of the treatment

More information

Considerations in antimicrobial prescribing Perspective: drug resistance

Considerations in antimicrobial prescribing Perspective: drug resistance Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,

More information

Pharmacology Week 6 ANTIMICROBIAL AGENTS

Pharmacology Week 6 ANTIMICROBIAL AGENTS Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory

More information

Rational use of antibiotics

Rational use of antibiotics Rational use of antibiotics Uga Dumpis MD, PhD,, DTM Stradins University Hospital Riga, Latvia ugadumpis@stradini.lv BALTICCARE CONFERENCE, PSKOV, 16-18.03, 18.03, 2006 Why to use antibiotics? Prophylaxis

More information

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae

ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;

More information

Antibiotic Usage Guidelines in Hospital

Antibiotic Usage Guidelines in Hospital SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information